WO2020214867A1
|
|
Methods and uses of variant icos ligand (icosl) fusion proteins
|
WO2020113141A2
|
|
Cd86 variant immunomodulatory proteins and uses thereof
|
WO2020061376A2
|
|
Methods and uses of variant cd80 fusion proteins and related constructs
|
WO2019241758A1
|
|
Pd-1 variant immunomodulatory proteins and uses thereof
|
CA3087149A1
|
|
Multi-domain immunomodulatory proteins and methods of use thereof
|
US2020283500A1
|
|
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
CN111801347A
|
|
CTLA-4 variant immunomodulatory proteins and uses thereof
|
KR20190141146A
|
|
PD-L2 variant immunomodulatory protein and uses thereof
|
AU2018236224A1
|
|
PD-L1 variant immunomodulatory proteins and uses thereof
|
EP3596114A2
|
|
Cd80 variant immunomodulatory proteins and uses thereof
|
CA3040296A1
|
|
Secretable variant immunomodulatory proteins and engineered cell therapy
|
WO2018022945A1
|
|
Cd112 variant immunomodulatory proteins and uses thereof
|
CN110088127A
|
|
CD155 variant immune modulator and application thereof
|
KR20190005879A
|
|
ICOS ligand mutant immunoregulatory proteins and uses thereof
|
KR20190006495A
|
|
CD80 variant immunoregulatory proteins and uses thereof
|
CN108513576A
|
|
Adjustable variant immunoglobulin superfamily structural domain and engineered cell therapy
|
US2019040014A1
|
|
Solid forms of an S-Nitrosoglutathione reductase inhibitor
|
CN107969128A
|
|
Immune modulator with adjustable affinity
|